Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab vs Cisplatin with TPF Induction in Locally Advanced NPC
NCT03557112Phase 2Unknown
- Sponsor
- Guizhou Medical University
- Start
- Jun 2018
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Guizhou Medical University. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03557112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557112.